CLARITHROMYCIN
Details
- Status
- Prescription
- First Approved
- 2004-05-25
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE, TABLET, FOR SUSPENSION
Companies
CLARITHROMYCIN Approval History
What CLARITHROMYCIN Treats
10 indicationsCLARITHROMYCIN is approved for 10 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Acute Bacterial Exacerbation of Chronic Bronchitis
- Acute Maxillary Sinusitis
- Community-Acquired Pneumonia
- Pharyngitis
- Tonsillitis
- Skin and Skin Structure Infections
- Acute Otitis Media
- Mycobacterial Infections
Drugs Similar to CLARITHROMYCIN
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CLARITHROMYCIN FDA Label Details
ProIndications & Usage
FDA Label (PDF)Clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults Acute Maxillary Sinusitis Community-Acquired Pneumonia Pharyngitis/Tonsillitis Uncomplicated Skin and Skin Structure Infections Acute Otitis Media in Pediatric Patients Treatment and Prophylaxis of Disseminated Mycobacterial Infections Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults Limitations of Use To reduce the development of drug-resistant bacteria and maintain the ...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.